BR112022009708A2 - Métodos de tratamento de câncer com uso de inibidores dkk-1 - Google Patents

Métodos de tratamento de câncer com uso de inibidores dkk-1

Info

Publication number
BR112022009708A2
BR112022009708A2 BR112022009708A BR112022009708A BR112022009708A2 BR 112022009708 A2 BR112022009708 A2 BR 112022009708A2 BR 112022009708 A BR112022009708 A BR 112022009708A BR 112022009708 A BR112022009708 A BR 112022009708A BR 112022009708 A2 BR112022009708 A2 BR 112022009708A2
Authority
BR
Brazil
Prior art keywords
cancer
dkk
inhibitors
treatment
methods
Prior art date
Application number
BR112022009708A
Other languages
English (en)
Inventor
H Kagey Michael
Somala Naik Girish
A Sirard Cynthia
Original Assignee
Leap Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leap Therapeutics Inc filed Critical Leap Therapeutics Inc
Publication of BR112022009708A2 publication Critical patent/BR112022009708A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

MÉTODOS DE TRATAMENTO DE CÂNCER COM USO DE INIBIDORES DKK-1. Trata-se de um método de tratamento de um indivíduo que sofre de um câncer, que compreende as etapas de obter uma amostra de uma célula cancerígena do indivíduo; determinar uma sequência de uma proteína de subunidade catalisadora de fosfatidilinositol 3-quinase (PIK3CA) na amostra; e administrar uma primeira quantidade de um inibidor DKK1 ao indivíduo determinado a ter a sequência de proteína PIK3CA que inclui uma mutação de ativação. O câncer é um câncer de endométrio epitelial ou um câncer de ovário epitelial.
BR112022009708A 2019-11-22 2020-11-23 Métodos de tratamento de câncer com uso de inibidores dkk-1 BR112022009708A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962939174P 2019-11-22 2019-11-22
PCT/US2020/061773 WO2021102403A1 (en) 2019-11-22 2020-11-23 Methods of treating cancer using dkk-1-inhibitors

Publications (1)

Publication Number Publication Date
BR112022009708A2 true BR112022009708A2 (pt) 2022-08-09

Family

ID=73834617

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022009708A BR112022009708A2 (pt) 2019-11-22 2020-11-23 Métodos de tratamento de câncer com uso de inibidores dkk-1

Country Status (11)

Country Link
US (1) US20240141023A1 (pt)
EP (1) EP4061419A1 (pt)
JP (1) JP2023502666A (pt)
KR (1) KR20220131223A (pt)
CN (1) CN114929275A (pt)
AU (1) AU2020386091A1 (pt)
BR (1) BR112022009708A2 (pt)
CA (1) CA3158661A1 (pt)
IL (1) IL293090A (pt)
MX (1) MX2022006031A (pt)
WO (1) WO2021102403A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024015463A1 (en) * 2022-07-12 2024-01-18 Leap Therapeutics, Inc. Combination therapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5475120A (en) 1990-11-02 1995-12-12 University Of Florida Method for the isolation and purification of taxol and its natural analogues
US5194635A (en) 1991-03-18 1993-03-16 Virginia Tech Intellectual Properties, Inc. Rearranged taxol compounds and method of using in testing of in vivo activity
US5488116A (en) 1992-03-30 1996-01-30 Sloan-Kettering Institute For Cancer Research Total synthesis of taxol and analogues thereof
US5416225A (en) 1992-03-30 1995-05-16 Sloan-Kettering Institute For Cancer Research Total synthesis of taxol
EP0639186B1 (en) 1992-04-17 1999-06-23 Abbott Laboratories Taxol derivatives
US5440056A (en) 1992-04-17 1995-08-08 Abbott Laboratories 9-deoxotaxane compounds
US5461169A (en) 1992-06-23 1995-10-24 The Scripps Research Institute Total synthesis of taxol and taxol analogs
US5440057A (en) 1993-08-20 1995-08-08 The Scripps Research Institute Access to taxol analogs
WO1994005282A1 (en) 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
US5478854A (en) 1992-10-01 1995-12-26 Bristol-Myers Squibb Company Deoxy taxols
US5411984A (en) 1992-10-16 1995-05-02 Virginia Tech Intellectual Properties, Inc. Water soluble analogs and prodrugs of taxol
CA2126698A1 (en) 1992-12-07 1994-06-23 Muraleedharan G. Nair Process for the isolation and purification of taxol and taxanes from taxus spp.
US5468769A (en) 1993-07-15 1995-11-21 Abbott Laboratories Paclitaxel derivatives
FR2707642B1 (fr) 1993-07-16 1995-10-13 Electricite De France Dérivés de polyéthers et d'hétérocycles pentacycliques, leurs polymères et leurs applications, notamment à la complexation d'ions métalliques.
US5405972A (en) 1993-07-20 1995-04-11 Florida State University Synthetic process for the preparation of taxol and other tricyclic and tetracyclic taxanes
US5565478A (en) 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US5508447A (en) 1994-05-24 1996-04-16 Board Of Regents, The University Of Texas System Short synthetic route to taxol and taxol derivatives
US5489589A (en) 1994-12-07 1996-02-06 Bristol-Myers Squibb Company Amino acid derivatives of paclitaxel
US7446181B2 (en) 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
AR075989A1 (es) 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
CA2783665A1 (en) * 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
KR20190085935A (ko) * 2016-10-26 2019-07-19 리프 테라퓨틱스 인코포레이티드 항-dkk-1 항체를 사용하여 암을 치료하기 위한 바이오마커로서의 베타-카테닌의 용도

Also Published As

Publication number Publication date
EP4061419A1 (en) 2022-09-28
MX2022006031A (es) 2022-07-19
JP2023502666A (ja) 2023-01-25
US20240141023A1 (en) 2024-05-02
WO2021102403A1 (en) 2021-05-27
IL293090A (en) 2022-07-01
KR20220131223A (ko) 2022-09-27
AU2020386091A1 (en) 2022-06-09
CA3158661A1 (en) 2021-05-27
CN114929275A (zh) 2022-08-19

Similar Documents

Publication Publication Date Title
MX2022006075A (es) Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer.
Bateman et al. Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients
MY198081A (en) Urinalysis device and dry reagent for quantitative urinalysis
BR112022024755A2 (pt) Composição, kit e método para detectar sars-cov-2 e uso dos mesmos
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
SG11202012585YA (en) Hydroxymethylation analysis of cell-free nucleic acid samples for assigning tissue of origin, and related methods of use
BR112017021305A2 (pt) dispositivo de teste de fluxo lateral, e, método e kit para detecção quantitativa de um analito em uma amostra de saliva
BR112018074853A2 (pt) métodos para detectar a presença de pelo menos um genogrupo de norovírus em uma amostra de fezes e para selecionar um paciente que sofre de gastroenterite aguda, e, kit
BR112023009531A2 (pt) Gcn2 e inibidores de perk quinase e métodos de uso dos mesmos
BR112016002845A2 (pt) composições e métodos para tratar condições associadas ao complemento
BR112022007386A2 (pt) Métodos para tratar um câncer hematológico e o uso de biomarcadores companheiros para 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)isoindolina-1,3-diona
BR112022003335A2 (pt) Conjugados de il-2 e métodos de uso para tratar doenças autoimunes
BR112018073178A2 (pt) método, matriz e uso dos mesmos
BR112018008799A2 (pt) método de prognóstico
MX2019005443A (es) Combinacion de un inhibidor de brd4 y un antifolato para la terapia del cancer.
BR112022009708A2 (pt) Métodos de tratamento de câncer com uso de inibidores dkk-1
Saadeh et al. Procoagulant activity in gynaecological cancer patients; the effect of surgery and chemotherapy
WO2019074615A3 (en) In vitro methods for skin therapeutic compound discovery using skin age biomarkers
AU2018286823A1 (en) Compressible extraction instrument for pretreating a sample
BR112016019740A2 (pt) monitoramento do estado de inflamação
BR112021012056A2 (pt) Inibidor da expressão gênica do hbv, agente que reduz a carga antigênica de hbv, composições para uso no tratamento de uma infecção crônica por hbv, usos de um inibidor da expressão gênica do hbv e de um agente que reduz a carga antigênica de hbv, métodos de tratamento da infecção crônica por hbv e kit
WO2022119830A8 (en) Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy
BR112022004972A2 (pt) Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso
MX2019003569A (es) Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos.
AU2021269176A8 (en) Single domain antibodies binding to SARS-CoV-2 spike protein